ES2052368T3 - Factores sanguineos producidos por recombinacion y el proceso para la expresion de dichos factores, asi como recombinacion del virus de vaccina usados en dicho proceso. - Google Patents

Factores sanguineos producidos por recombinacion y el proceso para la expresion de dichos factores, asi como recombinacion del virus de vaccina usados en dicho proceso.

Info

Publication number
ES2052368T3
ES2052368T3 ES91903050T ES91903050T ES2052368T3 ES 2052368 T3 ES2052368 T3 ES 2052368T3 ES 91903050 T ES91903050 T ES 91903050T ES 91903050 T ES91903050 T ES 91903050T ES 2052368 T3 ES2052368 T3 ES 2052368T3
Authority
ES
Spain
Prior art keywords
recombination
factors
well
expression
blood factors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91903050T
Other languages
English (en)
Inventor
Falko-Gunter Falkner
Ross T A Macgillivray
Walter Bodemer
Friedrich Scheiflinger
Johann Eibl
Friedrich Dorner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno AG filed Critical Immuno AG
Application granted granted Critical
Publication of ES2052368T3 publication Critical patent/ES2052368T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Auxiliary Devices For Machine Tools (AREA)
  • Gear Processing (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE DESCRIBEN FACTORES SANGUINEOS PRODUCIDOS DE FORMA RECOMBINANTE ASICOMO UN PROCESO PARA SU PREPARACION, DICHOS FACTORES SANGUINEOS TIENEN UNA PROPORCION DE FORMA BIOLOGICAMENTE ACTIVA CON RELACION A LA FORMA ANTIGENICA DE AL MENOS EL 50%, PREFERIBLEMENTE EN EL RANGO DE ENTRE EL 60 Y 90%. SE PRESENTAN UNOS VIRUS RECOMBINANTES PARA UNA VACUNA USADOS EN EL MENCIONADO PROCESO. EL PROCESO DE ACUERDO CON ESTA INVENCION SUMINISTRA UN SISTEMA DE EXPRESION MEJORADO CON UNA ALTA CAPACIDAD POST TRANSLACIONAL BAJO CONDICIONES DE EXPRESION ESTABLES.
ES91903050T 1990-01-26 1991-01-24 Factores sanguineos producidos por recombinacion y el proceso para la expresion de dichos factores, asi como recombinacion del virus de vaccina usados en dicho proceso. Expired - Lifetime ES2052368T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90101623 1990-01-26

Publications (1)

Publication Number Publication Date
ES2052368T3 true ES2052368T3 (es) 1994-07-01

Family

ID=8203546

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91903050T Expired - Lifetime ES2052368T3 (es) 1990-01-26 1991-01-24 Factores sanguineos producidos por recombinacion y el proceso para la expresion de dichos factores, asi como recombinacion del virus de vaccina usados en dicho proceso.

Country Status (12)

Country Link
EP (1) EP0512011B1 (es)
JP (1) JP2549224B2 (es)
AT (1) ATE103982T1 (es)
CA (1) CA2073859A1 (es)
CS (1) CS17291A2 (es)
DE (2) DE69101634T4 (es)
DK (1) DK0512011T3 (es)
ES (1) ES2052368T3 (es)
FI (1) FI923347A7 (es)
HU (1) HUT63459A (es)
NO (1) NO922953L (es)
WO (1) WO1991011519A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229390T2 (de) * 1991-08-26 1999-11-11 Immuno Ag, Wien Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus
US5527692A (en) * 1991-12-31 1996-06-18 Zymogenetics, Inc. Methods for producing thrombin
AU683834B2 (en) * 1991-12-31 1997-11-27 Zymogenetics Inc. Methods for producing thrombin
ATE293168T1 (de) * 1993-11-12 2005-04-15 Gilead Sciences Inc Thrombin mutanten
US7060484B1 (en) 1993-11-12 2006-06-13 Gilead Sciences, Inc. Polypeptides and coagulation therapy
DE4430204A1 (de) * 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
AT403167B (de) * 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
AT404357B (de) * 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
HUP9700603A3 (en) * 1996-03-20 2001-08-28 Baxter Ag Pharmaceutical preparation for the treatment of blood coagulation disorders
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
EP1982732A3 (en) 2000-02-11 2011-06-08 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
US7572619B2 (en) * 2000-03-22 2009-08-11 Octagene Gmbh Recombinant blood clotting factors
EP1136553A1 (en) * 2000-03-22 2001-09-26 Octagene GmbH Production of recombinant blood clotting factors in human cell lines
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US7700733B2 (en) 2002-04-30 2010-04-20 Bayer Healthcare Llc Factor VII or VIIa polypeptide variants
DK2085470T3 (da) 2003-03-20 2012-08-06 Bayer Healthcare Llc FVII- eller FVIIa-varianter
DK1644504T3 (da) 2003-06-19 2010-05-25 Bayer Healthcare Llc Faktor VII- eller -VIIA-Gla-domænevarianter
JP6245299B2 (ja) * 2016-04-27 2017-12-13 バクスアルタ ゲーエムベーハー 組換え安定細胞クローン、その産生およびその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8508845D0 (en) * 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
JPH01502080A (ja) * 1986-11-17 1989-07-27 ニュー・イングランド・メディカル・センター 組み換えビタミンｋ依存性蛋白質のガンマカルボキシル化の増強
EP0380508A4 (en) * 1987-05-18 1991-04-03 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
DE3813093A1 (de) * 1988-04-19 1989-11-09 Immuno Ag Rekombinantes plasmid, verfahren zum herstellen eines rekombinanten avipoxvirus, rekombinantes avipoxvirus und dessen verwendung
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants

Also Published As

Publication number Publication date
EP0512011A1 (en) 1992-11-11
FI923347L (fi) 1992-07-23
DK0512011T3 (da) 1994-05-09
NO922953L (no) 1992-09-04
DE69101634T2 (de) 1994-08-18
HUT63459A (en) 1993-08-30
WO1991011519A1 (en) 1991-08-08
DE69101634T4 (de) 1994-12-01
DE69101634D1 (de) 1994-05-11
HU9202435D0 (en) 1992-10-28
JP2549224B2 (ja) 1996-10-30
CS17291A2 (en) 1991-09-15
NO922953D0 (no) 1992-07-24
FI923347A0 (fi) 1992-07-23
ATE103982T1 (de) 1994-04-15
JPH05507401A (ja) 1993-10-28
CA2073859A1 (en) 1991-07-27
EP0512011B1 (en) 1994-04-06
FI923347A7 (fi) 1992-07-23

Similar Documents

Publication Publication Date Title
ES2052478T1 (es) Particulas retrovirales no replicantes producidas de forma recombinante empleadas como agentes antivirales e inmunogenos.
ES2061500T3 (es) Diagnosis y vacunas de la hepatitis delta su preparacion y uso.
NO922953D0 (no) Rekombinant fremstilt blodfaktorer og fremgangsmaate for ekspresjon av blodfaktorene, samt vacciniavirusrekombinanter
ES2195998T3 (es) Sistemas de expresion de dna basados en alfavirus.
ES2089316T3 (es) Agente viral asociado con la enfermedad porcina misteriosa (mystery swine desease).
ES2166749T3 (es) Diagnosticos de nanbv: polinucleotidos utiles para discriminar virus de la hepatitis c.
ES2150595T3 (es) Procedimiento de preparacion de un vector viral de por lo menos 20 kb por recombinacion homologa intermolecular en una celula procariota.
ES2083764T3 (es) Vacuna contra el sindrome respiratorio reproductivo porcino (srrp) y diagnostico.
DE3586853D1 (de) Immunologisch aktive peptide, geeignet zur einfuehrung von immunisierung gegen malaria und deren kodierung von genen.
ES2099094T3 (es) Metodos y composiciones para tratamiento de interacciones hidrofobas patologicas en fluidos biologicos.
ES2054040T3 (es) Nueva forma galenica del fenofibrato.
AR004341A1 (es) Vacunas contra tumores y procedimiento para su produccion.
PE65198A1 (es) Virosomas cationicos como sistema de transferencia para material genetico
ES2061708T3 (es) Virus recombinante de la viruela de la gallina, vectores de expresion de proteinas heterologas y vacunas para aves de corral derivadas de este virus.
ES2134197T3 (es) Vacunas contra el virus del herpes simplex vp16.
ATE103297T1 (de) Peptid, immunogene zusammensetzung und impfstoff oder medizinische zubereitung, eine methode zur immunisierung eines saeugetieres gegen lhrh und methode zur verbesserung von mea.
ES2038689T3 (es) Procedimiento de cultivo del virus de la rinotraqueitis infecciosa de la pava, y vacuna preparada a partir del virus asi obtenido.
ES2115622T3 (es) Clones moleculares de hiv-1 y usos de los mismos.
ES2051830T3 (es) Solucion acuosa estable de anticuerpos.
AR246983A1 (es) Plasmido dna recombinante, linea celular y procedimiento para producir beta-ngf humano.
ES2077052T3 (es) Procedimiento para la incorporacion de o-hidroxifenil-s-triazinas a polimeros organicos.
ES2061603T3 (es) Mutantes viricos de la rinotraqueitis bovina infecciosa, vacunas que los contienen, metodos para la produccion de los mismos y metodos para el empleo de los mismos.
ES2111149T3 (es) Extracto a base de proteinas bacterianas, procedimiento para su preparacion y composicion farmaceutica que lo contiene.
ES2061850T3 (es) Virus recombinante de la enfermedad de marek, su procedimiento de preparacion y vacuna.
ES2137378T3 (es) Estructuras peptidicas poliramificadas para ser utilizadas contra el hiv.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 512011

Country of ref document: ES